Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.70 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985767 | 0.89 | TPMT (0.55) | TSHRAPOBEC3AHTTAPOBEC3GTNFRSF1A | |
| SCHEMBL28275397 | 0.87 | TUBB4A (0.55) | TSHRAPOBEC3AHTTAPOBEC3GLMNA | |
| SCHEMBL219096 | 0.87 | TUBB4A (0.55) | TSHRAPOBEC3AHTTAPOBEC3GLMNA | |
| SCHEMBL1134614 | 0.84 | TSHR (0.72) | TSHRAPOBEC3AHTTAPOBEC3GTNFRSF1A | |
| SCHEMBL1204414 | 0.84 | HTT (0.72) | TSHRAPOBEC3AHTTAPOBEC3GTNFRSF1A | |
| SCHEMBL30740894 | 0.84 | HTT (0.72) | TSHRAPOBEC3AHTTAPOBEC3GTNFRSF1A | |
| SCHEMBL30740936 | 0.82 | TSHR (0.70) | TSHRAPOBEC3AHTTAPOBEC3GTNFRSF1A | |
| SCHEMBL27914756 | 0.82 | TSHR (1.00) | TSHRAPOBEC3AHTTAPOBEC3GTNFRSF1A | |
| SCHEMBL31520156 | 0.82 | TSHR (0.70) | TSHRAPOBEC3AHTTAPOBEC3GTNFRSF1A | |
| SCHEMBL985988 | 0.81 | TSHR (0.44) | TSHRAPOBEC3AHTTAPOBEC3GLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-7235674-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7015328-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| EP-1392283-A4 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASE ACTIVATORS | CYTOVIA INC (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1392283-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002092076-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP1, CASP5 | TSHR 4830/4885APOBEC3A 1646/4885HTT 4701/4885 |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP5, CASP14 | TSHR 4833/4885APOBEC3A 1504/4885HTT 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.